ClinicalTrials.gg
CompletedNCT04951687ProCogUpdated May 23, 2023

Acute and Chronic Effects of Ecologic Barrier© on Mood and Cognition

An interventional study of Ecologic Barrier© and Placebo powder in Cognitive Change and Mood, sponsored by University of Reading. Completed at 1 site in United Kingdom. Open to participants aged 65 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by University of Reading · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Study summary

This study aims to investigate the acute and chronic effects of an 8 week probiotic intervention (Ecologic Barrier©) on mood and cognitive outcomes in healthy adults.

Read the detailed description

This study will employ a double-blind, randomised, placebo-controlled crossover design to investigate the acute and chronic effects of an 8 week probiotic intervention (Ecologic Barrier©) on mood and cognitive outcomes in healthy older adults. A total of 30 participants will be enrolled and counterbalanced to receive the active probiotic treatment (2g per day Ecologic Barrier©) or a matched placebo in the first arm, before having a 4 week washout period and continuing with 8 weeks of the second treatment not consumed within the first arm. Outcome measures will be assessed at baseline, 24 hours and 8 weeks within each arm. These will include cognitive measures of affective processing, immediate and delayed verbal memory, visuospatial working memory and executive functions, and mood measures of depressive symptoms, cognitive reactivity, anxiety, stress and general mood. In addition, faecal samples will be collected at all timepoints in order to explore faecal microbiota profiles before and after probiotic treatment.

02

Conditions studied

  • Cognitive Change
  • Mood
03

In context

Lead sponsor

University of Reading is the lead sponsor of 150 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 65 - 80
  • Agree not to not consume probiotic or prebiotic supplements or live yoghurt throughout the course of study.
  • Proficient in the English language

Exclusion criteria

Exclusion Criteria:

  • Already a habitual user of probiotics
  • Antibiotic treatment within last 3 months
  • Current diagnosis of and not currently receiving treatment for mental health disorder
  • Gastrointestinal disorder
  • Allergic to any ingredient of the active or placebo treatment
  • Regular smoker
  • Diabetes mellitus
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Active: Ecologic Barrier©

    Dietary supplement: Ecologic Barrier© Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate, and probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58). Subjects will consume 2g (5 billion CFU)/day of Ecologic Barrier©. The intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal.

    Dietary Supplement: Ecologic Barrier©

  • Placebo comparator
    Placebo

    Dietary supplement: placebo powder Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate. As with the active treatment, the intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal.

    Dietary Supplement: Placebo powder

Interventions

  • Dietary supplementEcologic Barrier©

    5x10\^9 CFU/ 2g per day of Ecologic Barrier©

  • Dietary supplementPlacebo powder

    matched placebo

06

What researchers measure

Primary outcomes

  1. Change in Corsi Block Tapping Test performance

    A standardised assessment of visuospatial working memory. The task comprises nine identical squares fixed in a random arrangement on a screen. Participants observe sequences of between two and nine blocks, which they then reproduce as accurately as possible. The dependent variable is the number of blocks pointed out in the correct order. Four versions of each sequence length are presented during the task. A novel sequence will be presented on each occasion, the order of which will be counterbalanced across participants.

    Time frame: Baseline, 24 hours and 8 weeks

  2. Change in Immediate Word Recall from the Rey Auditory Verbal Learning Task

    Participants will be presented with a sequential list of 15 words, at a rate of 1 word per second. The participant will then have 60s to say out loud as many of these words as possible, with the resulting score recorded as a percentage of accuracy.

    Time frame: Baseline, 24 hours and 8 weeks

Secondary outcomes

  1. Rey Auditory Verbal Learning Task - Delayed Word Recall

    After a period of time subject are asked to recall as many words as possible from list A

    Time frame: Baseline, 24 hours and 8 weeks

  2. Rey Auditory Verbal Learning Task - Word Recognition

    Following the delayed word recall, words from list A, list B and novel words are displayed sequentially on the screen and participants are asked to indicate which words were from list A only.

    Time frame: Baseline, 24 hours and 8 weeks

  3. Switching task

    This task requires executive function and sustained attention, and provides a measure of cognitive flexibility. Participants view a circle with 8 equally spaced radii 2 of which form a bold bisecting line. Numbers are chosen randomly from a set of 1-4 \& 6-9 and displayed sequentially in a clockwise direction. A response of higher or lower than 5 is made for trials below the bold line, and even or odd for numbers above the line. Outcome measures include overall accuracy and reaction time (RT) on correct trials, as well as accuracy and RT on trials where there is a 'switch cost' from stimuli moving from below to above the bold line and vice versa.

    Time frame: Baseline, 24 hours and 8 weeks

  4. Go/No Go task

    This task measures executive function - specifically the ability to inhibit or withhold a response to no-go stimuli. Both a neutral block (white circles) and an emotional block (happy and fearful faces from the FACES database) are included here, in order to explore any additional influence of emotional stimuli on inhibitory responses. Outcome measures include accuracy and reaction time (RT). Accuracy and reaction times in the emotional blocks may also be correlated with responses to mood measures.

    Time frame: Baseline, 24 hours and 8 weeks

  5. Leiden Index of Depression Sensitivity revised (LEIDS-r)

    A validated questionnaire measure of cognitive reactivity. The LEIDS-r comprises of 34 items which the participant rate on a scale from 0-4 to indicate how strongly each statement applied to them when they are feeling somewhat sad.

    Time frame: Baseline, 24 hours and 8 weeks

  6. Positive and Negative Affect Schedule expanded (PANAS-x)

    A validated self-report measure of affective state. The PANAS comprises of two distinct affective states (positive and negative), as well as 11 individual affective states (fear, guilt, sadness, surprise, hostility, shyness, joviality, self-assurance, attentiveness, fatigue and serenity. Subjects use a likert scale from 1 - 5 to indicate how the word relates to how they are currently feeling. As this analysis is exploratory all affective states will be explored.

    Time frame: Baseline, 24 hours and 8 weeks

  7. State Trait Anxiety Inventory

    A well validated scale for assessing self-reported state and trait anxiety. In line with the study objectives, only the state items will be used to assess current feelings of anxiety in the participants. This includes 10 items which are rated using a 4-point likert scale.

    Time frame: Baseline, 24 hours and 8 weeks

  8. Perceived Stress Scale

    A validated 10 item scale for self-reporting levels of perceived stress over the last month. Items are rated using a 5-point likert scale.

    Time frame: Baseline and 8 weeks

  9. Centre for Epidemiological Studies Depression Scale (CESD)

    A validated, brief self report measure of depressive symptoms commonly used to assess sub-clinical levels of low mood. Items are responded to using a 4-point likert scale. Scores range from 0 to 60, with high scores indicating greater depressive symptoms.

    Time frame: Baseline and 8 weeks

Other outcomes

  1. Faecal sample analysis

    16S rRNA sequencing for classification and quantification of faecal bacteria

    Time frame: Baseline, 8 weeks

  2. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) is a short cognitive screening tool to indicate current cognitive status. It is similar to the Mini Mental State Examination, but more sensitive to Mild Cognitive Impairment. Results will not be used to screen for eligibility, but baseline MoCA score may be included as covariate.

    Time frame: Baseline (arm 1 only)

  3. Epic-Norfolk Food Frequency Questionnaire (FFQ)

    The FFQ is a validated tool for gauging the average habitual dietary intake of micro and macronutrients of an individual in the UK, which is particularly important to explore in order to understand how the probiotic supplement may interact with diet and gut microbiome diversity. Data will be processed using the FETA software.

    Time frame: Baseline (arm 1 only)

07

Study locations

1 site
  • School of Psychology and Clinical Languages
    Reading, RG6 6BZ, United Kingdom
08

References and documents

Publications

  • Eastwood J, van Hemert S, Stolaki M, Williams C, Walton G, Lamport D. Exploring the acute and chronic effects of a multistrain probiotic supplement on cognitive function and mood in healthy older adults: a randomized controlled trial. Am J Clin Nutr. 2025 Jun;121(6):1268-1280. doi: 10.1016/j.ajcnut.2025.04.002. Epub 2025 Apr 11. PubMed 40222448 ↗

Study documents

  • Study protocol · Dec 29, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jul 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
Jul 7, 2021
StartActual
Aug 5, 2021
Primary completionActual
Jul 1, 2022
CompletionActual
Jul 1, 2022
Last update
May 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04951687
Collaborators
Winclove Probiotics B.V.
Responsible party
Prof Claire Williams (Professor, University of Reading) — Principal investigator
First posted
Jul 7, 2021
Start date
Aug 5, 2021
Primary completion
Jul 1, 2022
Completion
Jul 1, 2022
Last update
May 23, 2023

Study contacts

Daniel Lamport, Associate Prof
principal investigator · University of Reading
Saskia Van Hemert
study director · Winclove Probiotics B.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion